Table 1.
Baseline Patient Characteristics
| Value or no. of patients (%) | ||||
|---|---|---|---|---|
| WBRT group (n = 82) |
SRS group (n = 93) |
All patients (n = 175) | P value | |
| Age, years | .292 | |||
| Mean (SD) | 61. 8 (9.0) | 60.3 (9.4) | 61.0 (9.2) | |
| Range | 41–81 | 26–83 | 26–83 | |
| Age group | .456 | |||
| <60 years | 29 (35) | 38 (41) | 67 (38) | |
| ≥60 years | 53 (65) | 55 (59) | 108 (62) | |
| Sex | .606 | |||
| Female | 42 (51) | 44 (47) | 86 (49) | |
| Male | 40 (49) | 49 (53) | 89 (51) | |
| Duration of extracranial disease control before study entry * | .883 | |||
| ≤3 months | 45 (55) | 50 (54) | 95 (54) | |
| >3 months | 37 (45) | 43 (46) | 80 (46) | |
| No. of brain metastases | .643 | |||
| 1 | 65 (79) | 71 (76) | 136 (78) | |
| 2–4 | 17 (21) | 22 (24) | 39 (22) | |
| Histology of primary disease | .973 | |||
| Lung | 48 (58) | 56 (60) | 104 (59) | |
| Other | 25 (31) | 27 (29) | 52 (30) | |
| Radioresistant (melanoma, sarcoma, and renal cell carcinoma) | 9 (11) | 10 (11) | 19 (11) | |
| Resection cavity diameter | .821 | |||
| ≤3 cm | 48 (58) | 56 (60) | 104 (59) | |
| >3 cm | 34 (42) | 37 (40) | 71 (41) | |
| ELISA findings available at baseline * | .110 | |||
| Yes | 29 (35) | 44 (47) | 73 (42) | |
| No | 53 (65) | 49 (53) | 102 (58) | |
| Baseline ApoA1 | ||||
| n | 29 | 44 | 73 | |
| Median (IQR) | 108.9 (97.3–122.1) | 130.6 (105.6–158.5) | 116.2 (98.8–138.9) | |
| Range | 82.5–138.1 | 84.1–220.3 | 82.5–220.3 | |
| Baseline ApoE | ||||
| n | 29 | 44 | 73 | |
| Median (IQR) | 17.0 (12.4–25.0) | 29.4 (20.7–36.9) | 24.7 (15.0–34.1) | |
| Range | 3.4–52.7 | 10.7–47.4 | 3.4–52.7 | |
| Baseline ApoJ | ||||
| n | 29 | 44 | 73 | |
| Median (IQR) | 115.8 (94.6–145.2) | 134.9 (98.9–158.4) | 130.3 (97.8–150.0) | |
| Range | 84.5-194.6 | 82.8-218.9 | 82.8-218.9 | |
| Baseline amyloid beta | ||||
| n | 29 | 44 | 73 | |
| Median (IQR) | 66.5 (65.3–80.7) | 65.3 (40.7–78.9) | 65.3 (48.3–80.6) | |
| Range | 40.7–107.5 | 39.1–102.9 | 39.1–107.5 | |
| APOE genotype | .178 | |||
| E2E2 | 1 (1) | 0 (0) | 1 (1) | |
| E2E3 | 3 (4) | 12 (13) | 15 (9) | |
| E2E4 | 2 (2) | 3 (3) | 5 (2) | |
| E3E3 | 51 (62) | 52 (56) | 103 (59) | |
| E3E4 | 20 (25) | 15 (16) | 35 (20) | |
| E4E4 | 1 (1) | 2 (2) | 3 (2) | |
| Not measured | 4 (5) | 9 (10) | 13 (7) | |
| ECOG performance status score | .363 | |||
| 0 | 28 (34) | 36 (39) | 64 (36) | |
| 1 | 49 (60) | 47 (50) | 96 (55) | |
| 2 | 5 (6) | 10 (11) | 15 (9) | |
| Extent of surgery | .132 | |||
| Subtotal resection | 12 (15) | 7 (7) | 19 (11) | |
| Total (gross) resection | 70 (85) | 86 (93) | 156 (89) | |
| Surgical approach | .295 | |||
| Not reported | 0 | 1 | 1 | |
| En-Bloc | 51 (62) | 50 (54) | 101 (58) | |
| Piecemeal | 31 (38) | 42 (46) | 73 (42) |
Values are mean pg/mL (SD) for ApoE and amyloid beta, and mg/dL (SD) for ApoA and ApoJ. Abbreviations: ECOG, Eastern Cooperative Oncology Group; ELISA, enzyme-linked immunosorbent assay; SD, standard deviation; SRS, stereotactic radiosurgery; WBRT, whole-brain radiotherapy
*Defined as months of systemic disease control before study entry.
**In the interest of simplifying the analyses, we did not report ELISA (i.e., serum apolipoprotein) findings from patients without serum samples at baseline or from those with incomplete cognitive testing.